ArticleClinical Medicine Insights. Oncology2011
Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide.
Article in Clinical Medicine Insights. Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension.Journal of palliative medicine · 2015Trial
- Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis.Regional anesthesia and pain medicineTrial
- Lactulose Versus Naloxone for Opioid-Induced Constipation in Intensive Care.Turkish journal of pharmaceutical sciences · 2025Article
- Clinical Outcomes of Intravenous Methylnaltrexone in Children: A Single-Arm Retrospective Cohort Study.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024Article
- Opioid-induced Constipation: Old and New Concepts in Diagnosis and Treatment.Journal of neurogastroenterology and motility · 2024Review
- The Pharmacokinetics of Subcutaneous Methylnaltrexone Bromide in Rhesus Macaques (Journal of the American Association for Laboratory Animal Science : JAALAS · 2023Article
- Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.Advances in therapy · 2021Review
- Methylnaltrexone is safe in cancer patients with peritoneal carcinomatosis.Scientific reports · 2019Article
- New developments in the treatment of opioid-induced gastrointestinal symptoms.United European gastroenterology journal · 2018Review
- Constipation in specialized palliative care: factors related to constipation when applying different definitions.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes.Therapeutics and clinical risk management · 2016Article
- New Options in Constipation Management.Current oncology reports · 2015Review
- Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain.Journal of pain research · 2015Article
- Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.Journal of gastroenterology · 2014Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Constipation, one of the major side effects of opiates used in palliative care, can impair patients' quality of life to a point where it prevents sufficient pain control. Methylnaltrexone is a novel μ-receptor antagonist, which does not pass the blood brain barrier. It is licensed to treat opiate induced constipation for patients with advanced diseases. This review article presents an overview of pharmacology and safety of its application, evidence of its efficacy and economic aspects of its use in clinical practice. Available data are limited but strongly suggest that methylnaltrexone causes laxation in less than 24 hours for at least half of those patients over the first two weeks of usage without impairing pain control or causing serious adverse effects. To avoid danger of gastrointestinal perforation it is contraindicated for patients at risk for that complication. More research is needed to evaluate its long-term efficacy and economic impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.